




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12P 21/04, 21/02, C12N 1/14		A1	(11) International Publication Number: WO 96/12032
			(43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: PCT/KR95/00131		(74) Agent: KIM, Jae, Cheon; Changlim Building, Suite 304, 816-3, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).	
(22) International Filing Date: 16 October 1995 (16.10.95)		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, IS, JP, KG, KP, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(30) Priority Data: 1994/26689 18 October 1994 (18.10.94) KR			
(71) Applicant (for all designated States except US): CHONG KUN DANG CORP. [KR/KR]; 410, Shindorim-dong, Guro-gu, Seoul 152-070 (KR).		Published - With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): KIM, Jung, Woo [KR/KR]; 925-7, Hwagog 1-dong, Kangseo-gu, Seoul 157-011 (KR). LEE, Kwang, Moo [KR/KR]; 201-705, Woosung Apartment, Pyungchon-dong, Dongan-gu, Anyang, Kyeonggi-do 430-070 (KR). CHOI, Byoung, Tack [KR/KR]; B-27, 647-41, Jeunnong-dong, Dongdaemun-gu, Seoul 130-020 (KR). LEE, Jin, Man [KR/KR]; 366-21, Gaebong 3-dong, Guro-gu, Seoul 152-093 (KR). SUNG, Nak, Kyu [KR/KR]; 1-102, Samho Apartment, Poil-dong, Duwang, Kyeonggi-do 437-120 (KR). MIN, Kyeong, Bok [KR/KR]; 1626-23, Bongchun 7-dong, Kwanag-gu, Seoul 151-057 (KR).			

(54) Title: PROCESS FOR MANUFACTURING CYCLOSPORIN A BY HIGHLY PRODUCTIVE FUSANT STRAIN

(57) Abstract

The present invention relates to a process for making a highly productive fusant of *Tolypocladium inflatum*, a producing strain of cyclosporin A with immunosuppressive property wherein the selection of the fusant KD461, designed to produce a large amount of cyclosporin A, was made available by the following steps of: developing amino acid-dependent mutant of *Tolypocladium inflatum*, wild strain isolated from soil, which induced by UV radiation: conjugating L-valine-dependent and L-leucine-dependent mutant to promote the demand and utility of L-valine and L-leucine, precursors of cyclosporin A, together with organic nitrogen-source. The fusant KD461 has following characteristics in comparison with wild strain: a) in a solid medium, slowly growing in a malt-yeast extract agar medium, b) darker as light grey color in colony, c) backside of colony with dark brown, d) in a liquid medium short and thick hyphae with many arthrospore.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROCESS FOR MANUFACTURING CYCLOSPORIN A BY
HIGHLY PRODUCTIVE FUSANT STRAIN

5 FIELD OF THE INVENTION

The present invention relates to a microbial process for making a highly productive fusant of *Tolypocladium inflatum*, a producer strain of cyclosporin A with immunosuppressive property and more particularly, to a method of producing cyclosporin A by submersed fermentation method
10 comprising the steps of : Based upon a wild strain *Tolypocladium inflatum* which produced a small amount of cyclosporin A, developing amino acid-dependent mutant strain induced by UV radiation : conjugating other two amino acid-dependent mutants; making a highly productive fusant strain of cyclosporin A in parallel with increasing demanding of amino
15 acid and organic nitrogen-source : and establishing the suitable condition and method of culture to these fusant to obtain the cyclosporin A by submersed fermentation method.

DESCRIPTION OF THE PRIOR ART

20 In more detail, *Tolypocladium inflatum* Gams NRRL 8044, a producer strain of cyclosporin A, is fungus and cyclosporin A which this strain produces is cyclic peptide consisting of 11 amino acids and molecular weight is 1,201, molecular formula is $C_{62}H_{111}N_{11}O_{12}$, and there are 25 derivatives according to variation of amino acids. [Traber R., HELVETICA
25 ACTA, 70,13(1987)]

Cyclosporin A, of which chemical name is Cyclo[{{(E)-(2S, 3R,4R)-3-hydroxy-4-methyl-2-(methyl-amino)-6-octenoyl}-L-2-aminobutyryl-N

-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-O-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl], is known to have antifungal, antiparasitic and antiinflammatory properties as well as a potent immunosuppressive property, and is important in the treatment of allograft rejection as well as autoimmune diseases[Borel 2 J.F., Prog. Allergy 38, 9 (1986)].

In general, the productive capacity of a producing strain is very important in producing secondary metabolites by fermentation of microorganisms.

10 *Sesquicillopsis rosariensis* G. ARNOLD F605 with 3150 mg/L and *Tolypocladium inflatum* Wb6-5 with 1100 mg/L (U.S. Pat. No. 5,256,547, 1993) are known as the highest productive strains among known cyclosporin A-producing strains.

15 The highly productive Cyclosporin A-forming strain among known strains has not been reported since cyclosporin A was for the first time isolated by A. Rueger et al. [Helv. Chem. Acta 59, 1075 (1976)], in spite of the fact that the highly productive mutant of *Tolypocladium inflatum* has been developed actively and used as industrial producing strain.

20 SUMMARY OF THE INVENTION

 The inventors made a highly productive cyclosporin A-forming mutant and invented a method for its fermentation. This mutant is characterized by producing cyclosporin A in high concentration, thus requiring large amounts of L-valine and L-leucine as well as organic nitrogen source to produce cyclosporin A.

 Cyclosporin A is cyclic peptide consisting of 11 amino acids : valine at position of 5, 11, leucine at position of 4, 6, 9, 10 and their

derivatives. *Tolypocladium inflatum* NRRL 8044, a cyclosporin A-producing strain, has known to produce cyclosporines selectively by adding special amino acids, the structural constituents of cyclosporines to a culture medium [H.Kobel, European J. Appl. Microbiol Biotechnol 14:237-240, 5 (1982)].

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is to chromatograms (A), (B) and (C) of cyclosporin A, pure product and cyclosporin A produced by wild strain KD01 and the 10 high-producing fusant KD 461 of *Tolypocladium inflatum*, respectively.

Figure 2 is to photographs (A) and (B) showing a colonial morphology of wild strain KD01 and the fusant KD 461 of *Tolypocladium inflatum* cultured in a malt-yeast extract medium, respectively.

Figure 3 is to photographs (A) and (B) showing a morphology of 15 hyphae, culturing wild strain KD01 and the fusant KD 461 of *Tolypocladium inflatum* in a liquid culture medium for 192 hours, respectively.

DETAILED DESCRIPTION OF THE INVENTION

The inventors made the targeted fusant with amplified cyclosporin 20 A-producing capability, where it comprises : as a method of amplifying production of cyclosporin A, mutating a poor producing strain of cyclosporin A, wild strain of *Tolypocladium inflatum* isolated from soil ; making L-valine-dependent mutant and L-leucine-dependent mutant, having a possibility to be precursor as constituent of target material, to 25 amplify dependence on each amino acids : fusing the cells of two amino acid-dependent mutants to increase dependence on both L-valine and L-leucine.

[Isolation of cyclosporin A-producing wild strain]

Cyclosporin A-producing wild strain, *Tolypocladium inflatum* KD01, was isolated from soil collected at Mt. Chiri in Chollabuk-do, Korea.

5 Soil sample was cultured on a solid medium supplemented with a small amount of ampicillin to isolate fungi, from which family *Moniliaceae* including *Tolypocladium inflatum* was isolated by taxonomical characteristics of fungus. The strain with antifungal property against *Aspergillus niger* was selected from isolated strains of
10 family *Moniliaceae* and then KD01 strain was selected from strains producing cyclosporin A corresponding with its pure product by TLC(Thin Layer Chromatography) and HPLC(High Performance Liquid Chromatography) analysis of their culture extract, identified as *Tolypocladium inflatum* with characteristics described as table 1 by a classified system of
15 fungus.

Isolated wild strain KD01 has low productivity of 175 mg cyclosporin A per liter. This strain has corresponding characteristics with *Tolypocladium inflatum* in terms of following : a) slow growth in a malt-yeast extract agar medium, b)formation of colony in white and with
20 5-6 mm of the diameter, c)no formation of sexual generation, d) formation of conidium with 1.8-3.0 X 1.4-2.0 μ m, oval form, hyaline and scar, e)conidiophores with bulbous form at base, and f)arthrospores with oval form in a liquid medium.

Table 1. Identification of *Tolypocladium inflatum* and soil-isolated strain

	Criteria for identification \ Strain	<i>Tolypocladium inflatum</i>	Soil-isolated strain KD01
5	I. Conidium		
	1. Conidium is formed directly from hyphae	0	0
	2. Conidium isn't a coiled form	0	0
10	3. Conidium and conidiopore are hyaline and bright color	0	0
	4. Typical conidium is a single cell with an oval form	0	0
15	II. Conidiophore		
	1. Conidiophore has an apparent form	0	0
	2. Conidiophore is clearly distinguished from conidium	0	0
20	3. Conidiophore is branched and phialides form in groups	0	0
	4. Lower portion of conidiophore is a bulbous form	0	0
25	III. Arthrospore		
	1. Arthrospore is connected with segments	0	0
	2. Arthrospore is a rod from	0	0

* H.L. Barnett, Illustrated Genera of Imperfect Fungi,
Burgess publishing Co. Minneapolis, 1972

[Selection of amino acid-dependent mutant]

Spore suspension ($10^9/\text{ml}$) of *Tolypocladium inflatum* KD01, a strain isolated from soil, was radiated by UV ray with the intensity of $300 \mu\text{W}/\text{cm}^2$ for 90 seconds to induce mutation, culturing for 20 hours in a nutrient medium to germinate. Spores and hyphae were collected from culture and further cultured for 20 hours in a minimum medium with ammonium sulfate and ampicillin, of which final concentration is 20mM and 3 mg/ml respectively, concentrating nitrogen source-dependent mutants.

After this suspension was spread in a complete medium and cultured at 28°C for 70 hours, appeared colonies were inoculated in minimum media and cultured at 28°C for 7 days. When fungus unable to grow in a minimum medium was inoculated in a minimal medium supplemented with amino acid of 1mM and cultured for 7 days, mutant strains, KD38 and KD94 which grew in a medium with L-valine or L-leucine, were obtained and identified as amino acid-dependent strains on L-valine and L-leucine.

[Preparation of protoplast and selection of fusant]

To prepare the fusant of L-valine-dependent mutant KD38 and L-leucine-dependent mutant KD94 from selected amino acid-dependent strains, protoplast of each amino acid-dependent mutant was prepared first by modified method of Peberdy et al. [(Peberdy, J.E., J.Gen. Microbiol. 69:325-330, (1971))].

It was first performed to prepare protoplast of individual amino acid-dependent mutant, which it comprises : suspending fungi with biomass 50 mg/ml in solution containing cell-wall hydrolase, novozyme and cellulase, with individual concentration of 5 mg/ml, incubating at 28°C

for 3 hours for removal of fungal cell-wall, obtaining protoplast of 5×10^8 /ml.

Protoplasts of KD38 and KD94 prepared in this way were mixed in equal amounts and fused in 30 % solution of polyethyleneglycol containing calcium chloride of 0.01 M and glycine of 0.05 M at 30 °C for 10 minutes. It was regenerated by the following modified method of Anne et al. [(Anne, J., J.Gen.Microbiol. 92:413-417, (1976)) : smearing in a regeneration medium (3 g N-NO₃, 0.5 g KCl, 0.5 g MgSO₄ · 7H₂O, 0.01 g FeSO₄ · 7H₂O, 1 g KH₂PO₄, 40 g glucose, 0.7 M NaCl, 2 g yeast extract, 18 g agar per liter), culturing at 28 °C for 5 days. Cell-fused strains, growing only in a medium with both L-valine and L-leucine, in frequency with 0.5 to 1.0 % by plating regenerated fungi in a minimum medium, used in the selection of amino acid-dependent strain, supplemented with L-valine, L-leucine and both of them.

After spreading the fusant on a solid complex medium, culturing for 5 to 6 days and obtaining colony, a highly productive fusant strain with large inhibition-zone was selected by bioassay using *Aspergillus niger* as test-microorganism.

The second selection of fusant, first selected in this way, occurs in a liquid medium culture to select a highly cyclosporin A-producing fusant, where it comprises : a second submersed culture of fusant, selected by bioassay using *Aspergillus niger*, in a medium supplemented with L-valine and L-leucine, analysis of the extract of the broth by HPLC. Selected fusant not only require more L-valine and L-leucine but also improved the productivity of cyclosporin A to the level of 8,920 mg/L, showing results of fermentation as the following Table 3. The highly productive fusant of present invention (KD 461) is deposited in

Korean Institute of Science and Technology on Mar. 7, 1994 under accession number KCTC 8556P. For the international patent application, it was converted the original deposit to a deposit under the Budapest Treaty in the Korean Institute of Science and Technology on November 30, 1994
5 under accession number KCTC 0130 BP.

A highly cyclosporin A-producing fusant was made from soil-isolated strain KD01, identified as *Tolypocladium inflatum*, and its mycological characteristics were described in Table 2, compared with mother wild strain.

10

1. Characteristics in an agar medium

The highly productive fusant KD461 of *Tolypocladium inflatum* KD01 directly isolated from soil has the following characteristics in comparison with originally occurring wild strain : slowly growing in a
15 malt-yeast extract agar medium; forming somewhat small colony, forming less aerial mycelium, having irregular wrinkles in the surface of colony; and extruding in middle portion. While the surface of colony of wild strain is smooth and white with light yellow backside of medium, that of the fusant KD461 is light gray with dark brown backside of medium (as
20 shown in Figure 2).

While mycelium of wild strain is slender and elongate with thickness of 1-2 μm , less branched, with a needle-shaped head, that of the fusant is to some extent thick and short with thickness of 2-3 μm , swollen in the middle, more branched, with a head not being slender.
25 Conidium of the fusant with about $1-2 \times 10^9$ CFU/ml, was less than that of wild strain with $2-3 \times 10^9$ CFU/ml.

Table 2. Comparison of mycological characteristics between soil-isolated strain, *Tolypocladium inflatum* KD01 and KD461

\Strain Characteristics	Mother strain of <i>Tolypocladium inflatum</i> KD01	Fusant <i>Tolypocladium inflatum</i> KD461
1. Morphology of colony	very short and elongate form of aerial hyphae with smooth and unfolded surface	low frequency of aerial hyphae, condensed hyphae with irregular wrinkles in the surface of colony
2. Size of colony (7 days)	5 - 6 mm	4 - 5 mm
3. Color of colony	hyaline hyphae, white colony	light gray
4. Color of backside	light yellow	dark brown
5. Conidium	egg-shaped or oval form 1.5-2.0 x 2.0-2.5 μ m	egg-shaped or oval form 1.0-1.5 x 1.5-2.0 μ m
6. Conidiophore	conidiophore of apparent form with round shape in lower portion	conidiophore of apparent and branched form with round shape in lower portion
7. Arthropore	oval form, 3-4 x 4-5 μ m	2-3 x 3-4 μ m
8. Production of cyclosporin A (mg/L)	175	8920

2. Characteristics in a liquid nutrient medium

The wild strain in a liquid nutrient medium has the following characteristics : vigorous proliferation, slender and elongated hyphae, formation of stroma in a definite size, rapid formation of arthrospores at 5 5-6 days of culture, production of cyclosporin A with gradual increase from 4 to 13 days of culture.

The fusant proliferates slowly more or less at early stage, with thick and short hyphae, many arthrospores(as shown in Figure 3). The production of cyclosporin A was shown to begin at 3 days and get to the 10 maximum at 12 days in comparison with the wild strain.

While the culture medium of the wild strain was light yellow color, that of the fusant was dark brown.

3. The productivity of cyclosporin A

15 1) Increased requirement of L-valine and L-leucine for cyclosporin A production

Mother strain KD01 and the fusant strain KD461, conjugated with L-valine-dependent strain and L-leucine-dependent strain, were cultured in a nutrient medium, using glucose as carbon source and meat peptone as 20 organic nitrogen source in various concentrations of L-valine and L-leucine, constituents of cyclosporin A. As a result, as shown in Table 3, the concentrations of L-valin and L-leucine were 4 g/L respectively for cyclosporin A maximal production whilst that of the fusant KD461 was increased up to 18 g/L, thus improving the production of cyclosporin A by 25 8920 mg/L. In other words, the fusant KD461 has recognized some unique properties in that it requires the large-scale amount of L-valine and L-leucine, precursor for the target compound and increases the production

of cyclosporin A.

Table 3. Feature in production of cyclosporin A in mother strain and the fusant KD 461 according to concentrations of L-valine and L-leucine

Addition of amino acids (g/L)		Production of cyclosporin A (mg/L)	
L-valin	L-leucine	Mother strain, KD01	Fusant, KD 461
1	0	45	1221
2	2	137	2180
4	4	175	3973
6	6	172	5810
10	10	170	7173
14	14	162	8379
18	18	131	8920
20	20	109	8159

2) Increase of the utility of organic nitrogen source

While mother strain KD01 requires mainly fine protein source such as peptone among many organic nitrogen sources for the production of cyclosporin A, a highly productive fusant KD461 has the increased proteolytic capability, in that it produces more amounts of cyclosporin A than known strain, using fine protein source like peptone as well as crude, cheap and natural protein sources like soybean meal, cottonseed meal, peanut meal and cornsteep loquor. Although the best organic nitrogen source is meat peptone, in the case of using as medium

constituents in combination with peptone and natural organic nitrogen sources like soybean meal, the production of cyclosporin A is increased more than using only natural organic nitrogen source.

5 3) Comparison with the known cyclosporin A-producing strain

While the productivity of known cyclosporin A-producing strain has been to have 1100 mg/L of mutant wb6-5 (IMET 43,899) of *Tolypocladium inflatum* and 3150 mg/L of mutant F605 of *Sesquicilliosis rosariensis* G. ARNOLD, the fusant KD 461 of present invention has high yield of 8920 mg/L (Table 4)

Table 4. Comparison productivity between known cyclosporin A-producing strain and the fusant KD461

15 Producing strain	<i>Tolypocladium inflatum</i> ATCC34921	<i>Tolypocladium inflatum</i> wb6-5	<i>Sesquicilliosis rosariensis</i> G. ARNOLD F605	Fusant, <i>Tolypocladium inflatum</i> KD 461
20 Basis	European J. App. Microbiol. & Biotech 34, 513-517, 1982	U.S Pat. No. 5, 256, 547	U.S Pat. No. 5, 256, 547	The Present Invention
25 Production of cyclosporin A (mg/L)	710	1100	3150	8920

The invention is described in more detail by the Examples as set forth hereunder.

5 [Example 1]

Strain : *Tolypocladium inflatum* KD 461

Pre-culture medium : Glucose 40 g/L, Bactopeptone 20 g/L,

Magnesium sulfate · 7H₂O 3 g/L,

Ferrous sulfate · 7H₂O 0.01 g/L,

10 Calcium phosphate 1 g/L,

Potassium chloride 1 g/L, ~

rice bran oil 1 g/L, pH 5.5

Producing medium : Glucose 120 g/L, Bactopeptone 20 g/L,

Ammonium sulfate · 7H₂O 10 g/L, L-valine

15 18 g/L, L-leucine 18 g/L, Ferrous sulfate

· 7H₂O 0.07 g/L, Zinc sulfate · 7H₂O 0.01 g/L,

Cupric sulfate · 5H₂O 0.0005 g/L, Manganese

chloride 0.002 g/L, pH 4.0-4.5

Culture-condition: Spore suspension, collected after incubation

20 in a malt-yeast extract agar medium, is

inoculated in pre-culture medium and

cultured at 28 °C with 220 rpm in a

rotatory shaker. 10 % portions of culture are

used to inoculated in a main medium and

25 cultured at 28 °C for 13 days with 220 rpm

in a rotatory shaker.

Analysis of the production : It was preformed as the following

processes: mixing for 13 days cultured
broth, 2N-Sodium hydroxide solution and
Butylacetate at the rate of 1 : 1 : 2 :
extracting, separating solvent layer,
5 vacuum drying; dissolving in mobile phase,
analysis by HPLC, of which example is
shown in figure 1. The volumetric productivity
of cyclosporin A by the fusant is 8920 mg/L.

Conditions for HPLC

10 Column : Develosil C8-3 (3 μ m, 4.6 X 75 cm)
Mobile phase : D.W. : ACN = 30 : 70
Temperature : 75 $^{\circ}$ C
Flow rate of mobile phase : 1.0 ml/min

15 [Example 2]

Strain and pre-culture medium are the same as in Example 1, using
bactopeptone 10 g/L and cornsteep liquor 10 g/L instead of bactopeptone
20 g/L in a main medium, yielding cyclosporin A of 8010 mg/L.

20 [Example 3]

Strain and pre-culture medium are the same as in Example 1,
performing pre-culture in a 7 L round-bottomed flask and main culture in
a 30 L fermentor. The culture in fermentor
occurs in the condition of temperature of 28 $^{\circ}$ C, aeration of 1vvm,
25 stirring at 500 rpm, period of 10 days. The yield of cyclosporin A was
7980 mg/L.

[Example 4]

Strain and pre-culture medium are the same as in Example 1, performing a first pre-culture in a 7 L round-bottomed flask and a second pre-culture in the same pre-culture medium in a 30 L fermentor and main culture in a 250 L fermentor at 28 °C, aeration of 1 VVM, stirring at 300 rpm for 10 days. The yield of cyclosporin A was 7710 mg/L.

10

15

20

25

Claims

5 1. A fusant KD461(Accession number KCTC 0130BP), conjugating
L-valine-dependent mutant and L-leucine-dependent mutant of wild
Tolypocladium inflatum, with the amplified productivity of cyclosporin A
by necessitating the demanding of L-valine and L-leucine, and expanding
the application of organic nitrogen source.

10

2. A Process for manufacturing cyclosporin A by fermentative and
cultivating method of a fusant KD461, L-valine and L-leucine-dependent
strain of *Tolypocladium inflatum*.

15

20

25

FIG. 1




FIG. 2



(A)


(B)

FIG. 3

(A)



(B)




BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Chong Kun Dang Corp.
410, Shindorim-dong, Guro-ku, Seoul 152-070
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Tolypocladium inflatum</i>	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0130BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on March 7 1994 and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on November 30 1994 .	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures (KCTC) Address: GERI, KIST PO Box 115, Yusong, Taejeon, 305-600 Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Kyung Seok Bae, Curator Date: December 07 1994

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 95/00131

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 P 21/04, 21/02; C 12 N 1/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 P 21/04, 21/02; c 12 N 1/14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

-

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 256 547 A (RUDAT et al.) 26 October 1993 (26.10.93), abstract.	1,2
A	DD 29 58 73 A5 (ARZNEIMITTELWERK DRESDEN) 14 November 1991 (14.11.91), claim 1. -----	1,2

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority-claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
22 December 1995 (22.12.95)Date of mailing of the international search report
29 December 1995 (29.12.95)Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Wolf e.h.
Telephone No. 1/53424/133

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 95/00131

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication	
US A	5256547	26-10-93	AT E	127528	15-09-95
			DE Co	5910642	12-10-95
			EP A1	507968	14-10-95
			EP B1	507968	06-09-95
			HU A2	616000	28-01-93
			HU A0	911160	28-10-91
			HU B	211026	28-09-95
DD A5	295873	14-11-91	keine - none - rien		